Puma Biotechnology
10880 Wilshire Boulevard
Suite 2150
Los Angeles
Caliornia
90024
United States
Tel: 310-443-4150
Fax: 310-443-4158
Website: http://www.pumabiotechnology.com/
Email: info@pumabiotechnology.com
421 articles about Puma Biotechnology
-
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
10/27/2022
Puma Biotechnology, Inc., a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung cancer patients at the EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics Symposium that is taking place in Barcelona, Spain.
-
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2022 Financial Results
10/20/2022
Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 3, 2022, following the release of its third quarter 2022 financial results.
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - October 04, 2022
10/4/2022
Puma Biotechnology, Inc., a biopharmaceutical company, announced that on October 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 26,875 shares of Puma common stock to five new non-executive employees.
-
Celltrion agreed Wednesday to jointly develop Abpro’s cancer molecule ABP-102 in a deal that could net as much as $1.75 billion. See inside for more cancer collaborations.
-
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
9/20/2022
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A.
-
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
9/11/2022
Puma Biotechnology, Inc. announced the presentation of updated findings from the Phase II SUMMIT basket trial of neratinib for HER2 -mutant, metastatic cervical cancer at the 2022 European Society for Medical Oncology Congress, currently taking place in Paris, France.
-
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at the hybrid H.C. Wainwright 24th Annual Global Investment Conference, which will be held September 12-14, 2022.
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Sep 02, 2022
9/2/2022
Puma Biotechnology, Inc., a biopharmaceutical company, announced that on September 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 18,750 shares of Puma common stock to two new non-executive employees.
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Aug 05, 2022
8/5/2022
Puma Biotechnology, Inc., a biopharmaceutical company, announced that on August 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 37,250 shares of Puma common stock to six new non-executive employees.
-
Puma Biotechnology Reports Second Quarter 2022 Financial Results
8/4/2022
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2022. Unless otherwise stated, all comparisons are for the second quarter of 2022 compared to the second quarter of 2021.
-
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2022 Financial Results
7/21/2022
Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 4, 2022, following the release of its second quarter 2022 financial results.
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - July 06, 2022
7/6/2022
Puma Biotechnology, Inc., a biopharmaceutical company, announced that on July 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 30,875 shares of Puma common stock to six new non-executive employees.
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 07, 2022
6/7/2022
Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 38,125 shares of Puma common stock to six new non-executive employees.
-
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
6/6/2022
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase II SUMMIT trial, assessing the efficacy of combined neratinib, fulvestrant, and trastuzumab in patients with hormone receptor positive, HER2-negative, HER2-mutant metastatic breast cancer, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting
6/4/2022
Puma Biotechnology, Inc., a biopharmaceutical company, presented final results from the Phase II SUMMIT ‘basket’ trial, assessing the efficacy of neratinib in treatment-refractory patients with metastatic biliary tract cancers with somatic HER2 mutations at the 2022 American Society of Clinical Oncology Annual Meeting.
-
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
5/26/2022
Puma Biotechnology, Inc., a biopharmaceutical company, announced the publication of two abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology Annual Meeting.
-
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 11, 2022
5/11/2022
Puma Biotechnology, Inc., a biopharmaceutical company, announced that on May 9, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 14,500 shares of Puma common stock to three new non-executive employees.
-
Puma Biotechnology Reports First Quarter 2022 Financial Results
5/5/2022
Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2022.
-
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
4/27/2022
Puma Biotechnology, Inc., a biopharmaceutical company, announced the release of titles of abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology Annual Meeting.
-
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2022 Financial Results
4/21/2022
Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 5, 2022, following the release of its first quarter 2022 financial results.